HomeCompareDRRX vs BTI

DRRX vs BTI: Dividend Comparison 2026

DRRX yields 104.71% · BTI yields 5.38%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 DRRX wins by $4.68M in total portfolio value
10 years
DRRX
DRRX
● Live price
104.71%
Share price
$1.91
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.71M
Annual income
$1,637,812.78
Full DRRX calculator →
BTI
BTI
● Live price
5.38%
Share price
$58.47
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.7K
Annual income
$2,786.64
Full BTI calculator →

Portfolio growth — DRRX vs BTI

📍 DRRX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDRRXBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DRRX + BTI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DRRX pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DRRX
Annual income on $10K today (after 15% tax)
$8,900.52/yr
After 10yr DRIP, annual income (after tax)
$1,392,140.86/yr
BTI
Annual income on $10K today (after 15% tax)
$457.40/yr
After 10yr DRIP, annual income (after tax)
$2,368.64/yr
At 15% tax rate, DRRX beats the other by $1,389,772.22/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DRRX + BTI for your $10,000?

DRRX: 50%BTI: 50%
100% BTI50/50100% DRRX
Portfolio after 10yr
$2.38M
Annual income
$820,299.71/yr
Blended yield
34.52%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

DRRX
Analyst Ratings
8
Buy
5
Hold
Consensus: Buy
Altman Z
-67.3
Piotroski
2/9
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.6% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DRRX buys
0
BTI buys
0
No recent congressional trades found for DRRX or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDRRXBTI
Forward yield104.71%5.38%
Annual dividend / share$2.00$3.15
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%11.3%
Portfolio after 10y$4.71M$37.7K
Annual income after 10y$1,637,812.78$2,786.64
Total dividends collected$4.23M$14.3K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy

Year-by-year: DRRX vs BTI ($10,000, DRIP)

YearDRRX PortfolioDRRX Income/yrBTI PortfolioBTI Income/yrGap
1← crossover$21,171$10,471.20$11,299$598.92+$9.9KDRRX
2$43,372$20,718.50$12,794$703.91+$30.6KDRRX
3$86,075$39,667.56$14,518$829.07+$71.6KDRRX
4$165,674$73,573.88$16,513$978.64+$149.2KDRRX
5$309,620$132,347.88$18,827$1,157.84+$290.8KDRRX
6$562,449$231,156.47$21,518$1,373.12+$540.9KDRRX
7$994,265$392,443.71$24,657$1,632.46+$969.6KDRRX
8$1,712,217$648,353.89$28,329$1,945.74+$1.68MDRRX
9$2,875,555$1,043,482.55$32,637$2,325.33+$2.84MDRRX
10$4,714,656$1,637,812.78$37,708$2,786.64+$4.68MDRRX

DRRX vs BTI: Complete Analysis 2026

DRRXStock

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Santen Pharmaceutical Co., Ltd. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.

Full DRRX Calculator →

BTIConsumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this DRRX vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DRRX vs SCHDDRRX vs JEPIDRRX vs ODRRX vs KODRRX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.